A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subject with Schizophrenia
Phase of Trial: Phase III
Latest Information Update: 24 May 2017
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 14 Oct 2016 Results of retrospective analysis of pooled data of this and other two trials (NCT01559272, NCT01515423) to characterize the population pharmacokinetics of paliperidone published in the Clinical Pharmacokinetics
- 15 Jul 2016 Planned locations also included Brazil, Bulgaria, Russia and South Africa.
- 27 Jun 2016 Results published in Janssen media release.